This webinar will focus on the implications of the Inflation Reduction Act (IRA) on value proposition development and the evidence needed for drugs launching in 2027-2028 that plan to seek reimbursement from Medicare. Join PRECISIONvalue’s Andrew Cournoyer and Precision Value & Health’s Ross Maclean for this value packed webinar.
The discussion will highlight key aspects of the IRA affecting drug developers including:
- Pricing implications and the unintended effect of the IRA on innovation
- Carving out drugs for small populations where the drug has only one indication
- How this Act is reshaping which indications to pursue and the ROI of a second/subsequent indication
- Will industry successfully lobby to reduce the IRA?
